Rules and Regulations of the State of Georgia
 

JavaScript Is Not Enabled alert

You need to have JavaScript enabled in your browser to utilise the full functionality of this website.

How to enable JavaScript in your browser






firefox Mozilla Firefox

  1. In the address bar, type about:config and press Enter.
  2. Click "I'll be careful, I promise" if a warning message appears.
  3. In the search box, search for javascript.enabled
  4. Toggle the "javascript.enabled" preference (right-click and select "Toggle" or double-click the preference) to change the value from "false" to "true".
  5. Click on the "Reload current page" button of the web browser to refresh the page.
  • 1. In the address bar, type about:config and press Enter.
  • 2. Click "I'll be careful, I promise" if a warning message appears.
  • 3. In the search box, search for javascript.enabled
  • 4. Toggle the "javascript.enabled" preference (right-click and select "Toggle" or double-click the preference) to change the value from "false" to "true".
  • 5. Click on the "Reload current page" button of the web browser to refresh the page.




ie Internet Explorer

  1. On web browser menu click "Tools" icon and select "Internet Options".
  2. In the "Internet Options" window select the "Security" tab.
  3. On the "Security" tab click on the "Custom level..." button.
  4. When the "Security Settings - Internet Zone" dialog window opens, look for the "Scripting" section.
  5. In the "Active Scripting" item select "Enable".
  6. When the "Warning!" window pops out asking "Are you sure you want to change the settings for this zone?" select "Yes".
  7. In the "Internet Options" window click on the "OK" button to close it.
  8. Click on the "Refresh" button of the web browser to refresh the page.
  • 1. ie9 01
  • 2. ie9 02
  • 3. ie9 03
  • 4. ie9 04
  • 5. ie9 05
  • 6. ie9 06
  • 7. ie9 07
  • 8. ie9 08
 Internet Explorer < 9
  1. On web browser menu click "Tools" and select "Internet Options"
  2. In the "Internet Options" window select the "Security" tab.
  3. On the "Security" tab click on the "Custom level..." button.
  4. When the "Security Settings - Internet Zone" dialog window opens, look for the "Scripting" section.
  5. In the "Active Scripting" item select "Enable".
  6. When the "Warning!" window pops out asking "Are you sure you want to change the settings for this zone?" select "Yes".
  7. In the "Internet Options" window click on the "OK" button to close it.
  8. Click on the "Refresh" button of the web browser to refresh the page.
  • 1. ie 01
  • 2. ie 02
  • 3. ie 03
  • 4. ie 04
  • 5. ie 05
  • 6. ie 06
  • 7. ie 07
  • 8. ie 08




chrome Google Chrome

  1. On the web browser menu click on the "Customize and control Google Chrome" and select "Settings".
  2. In the "Settings" section click on the "Show advanced settings..."
  3. Under the the "Privacy" click on the "Content settings...".
  4. When the dialog window opens, look for the "JavaScript" section and select "Allow all sites to run JavaScript (recommended)".
  5. Click on the "OK" button to close it.
  6. Close the "Settings" tab.
  7. Click on the "Reload this page" button of the web browser to refresh the page.
  • 1. chrome 01
  • 2. chrome 02
  • 3. chrome 03
  • 4. chrome 04
  • 5. chrome 05
  • 6. chrome 06
  • 7. chrome 07




opera Opera

  • 1. a) Click on "Menu", hover mouse on the "Settings" then hover mouse on the "Quick preferences" and mark the "Enable Javascript" checkbox.
  • 1. b) If "Menu bar" is shown click on the "Tools", hover mouse on the "Quick preferences" and mark the "Enable Javascript" checkbox.
1. a) opera10 a 1. b) opera10 b




safari Apple Safari

  1. On the web browser menu click on the "Edit" and select "Preferences".
  2. In the "Preferences" window select the "Security" tab.
  3. In the "Security" tab section "Web content" mark the "Enable JavaScript" checkbox.
  4. Click on the "Reload the current page" button of the web browser to refresh the page.
  • 1. safari 01
  • 2. safari 02
  • 3. safari 03
  • 4. safari 04
<xmp>.</xmp> <form name="form1" method="post" action="480-34?urlRedirected=yes&amp;data=admin&amp;lookingfor=480-34" id="form1"> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="/wEPDwUKLTY5ODkwOTM2Nw8WAh4Ec3BhbQIIFgJmD2QWAgIFDw8WAh4EVGV4dAUFNSArIDNkZGTvjQapWI+hl9vtEvh+ivVsM3BFfQ==" /> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="EEBB6393" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEWCAKmipX4CwLniKOhBALV5cpNAoa5iIEFAoznisYGAsrv5u0MAsrv4u0MAsrv3u0MajbtS7Xz7XuV/LdB1iFKKLLp8s4=" /> <div class='popup'> <div class='cnt223'> <div style="margin-bottom:6px;"> <img alt="Rules and Regulations of the State of Georgia" src="/images/new.gif"/> </div> <div class="header"> Terms and Conditions of Agreement for Access to Rules and Regulations of the State of Georgia Website </div> <div class="scroll"> <p>(Note: certain features of this site have been disabled for the general public to prevent digital piracy. If you are an entitled government entity pursuant the Georgia Administrative Procedures Act, <a target="_new" href="http://links.casemakerlegal.com/states/GA/books/Code_of_Georgia/browse?ci=25id=gasos&amp;codesec=50-13-7&amp;title=50&amp;#50-13-7(d)">O.C.G.A.§ 50-13-7(d)</a> contact the State of Georgia's Administrative Procedures Division at 678-364-3785 to enable these features for your location.)</p> <p>To access this website, you must agree to the following: </p> <p> These terms of use are a contract between you and/or your employer (if any), and Lawriter, LLC. </p> <p> You agree that you will not copy, print, or download anything from this website for any commercial use. </p> <p> You agree not to use any web crawler, scraper, or other robot or automated program or device to obtain data from the website.</p> <p> You agree that you will not sell, will not license, and will not otherwise make available in exchange for anything of value, anything that you download, print, or copy from this site.</p> <p> You agree that you will not copy, print, or download any portion of the regulations posted on this site exceeding a single chapter of regulations for sale, license, or other transfer to a third party, except that you may quote a reasonable portion of the regulations in the course of rendering professional advice.</p> <p> If you violate this agreement, or if you access or use this website in violation of this agreement, you agree that Lawriter will suffer damages of at least $20,000. </p> <p> THIS WEBSITE AND ITS CONTENT ARE PROVIDED "AS IS." THE STATE OF GEORGIA AND LAWRITER EXPRESSLY DISCLAIM ALL WARRANTIES, INCLUDING THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT AND ARE NOT LIABLE TO ANY PERSON FOR ANY ERRORS IN INACCURACIES CONTAINED IN THIS WEBSITE. </p> <p> If you accept these terms enter the information below and click “I AGREE”.</p> </div> <table border="0" style="width: 810px"> <tr> </tr> <tr> <td style="vertical-align: text-top; width: 243px;"> Full Name:</td> <td style="width: 532px; vertical-align:super;"> <input name="firstName" type="text" id="firstName" class="txt" /> <span id="lbl_fname"><font color="Red"></font></span> </td> </tr> <tr><td style="width: 243px"> Human verification: <b> <span id="lblStopSpam">5 + 3</span>&nbsp;= </b></td><td style="width: 532px"> <input name="captcha" type="text" id="captcha" class="txt" /> <span id="lbl_captcha"><font color="Red"></font></span> &nbsp; <input name="sum" type="hidden" id="sum" value="8" /> </td></tr> </table> <input type="submit" name="Button1" value="I AGREE" id="Button1" disabled="disabled" /> <span id="alrtmsg"><font color="Red"></font></span> <input name="v1" type="hidden" id="v1" /> <input name="v2" type="hidden" id="v2" /> <input name="v3" type="hidden" id="v3" /> <p>Privacy Policy: the above information is for internal use only as related to this agreement and will not be sold or distributed.</p> </div> </div> </form> <html> <head runat="server"> <title>GA - GAC</title> <link href="_files/main.css" media="all" rel="Stylesheet" type="text/css" /> <link href="_files/treeview_old.css" media="all" rel="Stylesheet" type="text/css" /> <link href="/_files/popup.css" media="all" rel="stylesheet" type="text/css" /> <script type="text/javascript" src="/_files/treeview.js"></script> <script type="text/javascript" src="/_files/jquery-1.8.0.min.js"></script> <script type="text/javascript" src="/_files/jquery-1.10.2.js"></script> <script type="text/javascript" src="/_files/popup.js"></script> <script type="text/javascript" src="http://code.jquery.com/jquery-1.8.2.js"></script> <script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js" /> <script type="text/javascript" src="/_files/jquery.popup.js"></script> <script type="text/javascript" src="/_files/jquery.popup.min.js"></script> <script type="text/javascript" src="/_files/ValidateForm.js"></script> <script src="https://code.jquery.com/jquery-1.11.3.js"></script> <link href="/_files/enablejs.css" rel="Stylesheet" type="text/css" /> <link href="/_files/forJavascript.css" rel="Stylesheet" type="text/css" /> <style type="text/css"> .collapse{background-image:url('/images/expcoll_right.png');} .expand{background-image:url('/images/expcoll_down.png');} </style> <script type="text/javascript"> $(document).ready(function(){ $("#History-parent").click(function(){ $("#History-Childs").toggle(); if ($('#History-parent img').hasClass('expand')) { $('#History-parent img').addClass('collapse'); $('#History-parent img').removeClass('expand'); $('#History-parent img').attr('src', '/images/expcoll_right.png'); } else { $('#History-parent img').removeClass('collapse'); $('#History-parent img').addClass('expand'); $('#History-parent img').attr('src', '/images/expcoll_down.png'); } }); $("#History-Childs").hide(); var tocnode=document.getElementById('toc-children'); if (tocnode != null) { if(tocnode.childNodes.length != 0) { document.getElementById("doc-content").style.width="72%"; document.getElementById("toc").style.width="21%"; document.getElementById("toc").style.padding="10px"; } else { document.getElementById('toc').style.display="none"; } } }); function fnsetRDVal(id) { if (id=="y") { document.getElementById("y").value="yes" document.getElementById("n").value="" } else { document.getElementById("n").value="no" document.getElementById("y").value="" } } </script> <script type="text/javascript"> function TermsCon() { var overlay = $('<div id="overlay"></div>'); overlay.show(); overlay.appendTo(document.body); $('.popup2').show(); $('#btnAgree').click(function () { $('.popup2').hide(); $("#overlay").hide(); overlay.appendTo(document.body).remove(); }); $("#btnprint").click(function () { var contents = $("#popupterms").html(); var frame1 = $('<iframe />'); frame1[0].name = "frame1"; frame1.css({ "position": "absolute", "top": "-1000000px" }); $("body").append(frame1); var frameDoc = frame1[0].contentWindow ? frame1[0].contentWindow : frame1[0].contentDocument.document ? frame1[0].contentDocument.document : frame1[0].contentDocument; frameDoc.document.open(); //Create a new HTML document. frameDoc.document.write('<html><head>'); frameDoc.document.write('</head><body>'); //Append the external CSS file. frameDoc.document.write('<link href="_files/popup.css" rel="stylesheet" type="text/css" />'); //Append the DIV contents. frameDoc.document.write(contents); frameDoc.document.write('</body></html>'); frameDoc.document.close(); setTimeout(function () { window.frames["frame1"].focus(); window.frames["frame1"].print(); frame1.remove(); }, 500); }); // alert("Because you do not agree to the Terms and Conditions for Access, you must cease accessing and/or using this website and destroy all material obtained from this website without your agreement."); // $('.popup2').show(); } </script> </head> <body> <div class="popup2"> <div class='cnt2231' id="popupterms"> <div style="margin-bottom: 6px;"> <img alt="Rules and Regulations of the State of Georgia" src="/images/new.gif" /> </div> <div class="header"> Terms and Conditions of Agreement for Access to Rules and Regulations of the State of Georgia Website </div> <div class="scroll" style="height:100%;"> <p>(Note: certain features of this site have been disabled for the general public to prevent digital piracy. If you are an entitled government entity pursuant the Georgia Administrative Procedures Act, <a target="_new" href="http://links.casemakerlegal.com/states/GA/books/Code_of_Georgia/browse?ci=25id=gasos&amp;codesec=50-13-7&amp;title=50&amp;#50-13-7(d)">O.C.G.A.§ 50-13-7(d)</a> contact the State of Georgia's Administrative Procedures Division at 678-364-3785 to enable these features for your location.)</p> <p>To access this website, you must agree to the following: </p> <p> These terms of use are a contract between you and/or your employer (if any), and Lawriter, LLC. </p> <p> You agree not to use any web crawler, scraper, or other robot or automated program or device to obtain data from the website. </p> <p> You agree that you will not sell or license anything that you download, print, or copy from this website.</p> <p> THIS WEBSITE AND ITS CONTENT ARE PROVIDED "AS IS." THE STATE OF GEORGIA AND LAWRITER EXPRESSLY DISCLAIM ALL WARRANTIES, INCLUDING THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT AND ARE NOT LIABLE TO ANY PERSON FOR ANY ERRORS IN INACCURACIES CONTAINED IN THIS WEBSITE. </p> <p> By accessing and/or using this website, you agree to the terms and conditions above. If you do not agree to the terms and conditions above, you must cease accessing and/or using this website and destroy all material obtained from this website without your agreement. </p> </div> </div> <div class="modal-footer"> <input type="button" name="btnAgree" value="Close" id="btnAgree" class="btn-blue noprint" /> <input type="button" name="btnprint" value="Print" id="btnprint" class="btn-blue noprint" /> </div> </div> </div> <div id="main" class="noprint"> <!--class="noprint"--> <div id="header" class="noprint"> <div class="container"> <div class="terms"> NOTICE OF TERMS OF USE OF THIS WEBSITE. By accessing and/or using this website, you agree to the following <a onclick="javascript:TermsCon();" style="text-decoration: underline">terms and conditions.</a> </div> <div class="content"> <div id="logo"> <!--<a href="../" title="Home"><img alt="Rules and Regulations of the State of Georgia" src="/images/garr_logo.gif" /></a>--> <!--<span id="georgia"><a href="/">Rules and Regulations of the State of Georgia</a></span>--> <a href="../" title="Home"><img alt="Rules and Regulations of the State of Georgia" src="/images/ga_rulesreg.gif" /></a> </div> <div id="links"> <a href="../home.aspx" class="constant" title="home">Home</a> | <a href="../gac/" class="constant" title="home">Browse</a> | <a href="../help.aspx" class="constant" title="help">Help</a> | <a href="http://sos.ga.gov/index.php/General/rules_and_regulations" target="_blank" onclick="void(0);" class="constant" title="Georgia SOS">Go to Georgia SOS</a> </div> </div> </div> <div class="sidebar"> <div id="full-text-search"> <form class="searchform" action="../search.aspx" method="get" onsubmit="javascript:return fncheckqts();"> <span class="searchHierarchy" style="margin-right:10px;" > <em class="mnemonic">H</em>ierarchy Search:&nbsp; <input onclick="fnsetRDVal(id);" id="y" checked="checked" type="radio" name="hierarchysearch" value="yes" />&nbsp;Y <input onclick="fnsetRDVal(id);" id="n" type="radio" name="hierarchysearch" value="" />&nbsp;N </span> <input id="query" name="query" class="searchfield" value="Search GA R&R...." onfocus="if (this.value == 'Search GA R&R....') {this.value = '';}" onblur="if (this.value == '') {this.value = 'Search GA R&R....';}" type="text" /> <input class="searchbutton" value="Go" type="submit" /> <input type="hidden" name="searchvalue" value="Chapter 480-34 CONTROLLED SUBSTANCES" /> <input type="hidden" id="msg" value="REPLACE_MESSAGE" /> <input type="hidden" name="from" value="gac" /> </form> </div> <!--<div id="full-text-search"> <form id="search" action="../search.aspx" method="get" onsubmit="javascript:return fncheckqts();"> <span class="searchHierarchy" style="margin-right:10px;" > <em class="mnemonic">H</em>ierarchy Search:&nbsp; <input onclick="fnsetRDVal(id);" id="y" checked="checked" type="radio" name="hierarchysearch" value="yes" />&nbsp;Y <input onclick="fnsetRDVal(id);" id="n" type="radio" name="hierarchysearch" value="" />&nbsp;N </span> <label for="query" accesskey="s"> <em class="mnemonic">S</em>earch GA R&R: </label><input type="hidden" name="from" value="gac" /> <input id="query" name="query" type="text" /> <input class="submit" value="Go" type="submit" /> <input type="hidden" id="msg" value="REPLACE_MESSAGE" /> <input type="hidden" name="searchlevel" value="REPLACE_SEARCHLEVEL" /> <input type="hidden" name="searchvalue" value="Chapter 480-34 CONTROLLED SUBSTANCES" /> </form> </div>--> <div id="searchcitation"> <form class="searchform" action="../search.aspx" method="get" onsubmit="javascript:return fnchecks();"> <div> <input id="section" name="section" class="searchfield" value="Go to Citation...." onfocus="if (this.value == 'Go to Citation....') {this.value = '';}" onblur="if (this.value == '') {this.value = 'Go to Citation....';}" type="text" /> <input class="searchbutton" value="Go" type="submit" /> <input type="hidden" name="from" value="gac" /> </div> </form> </div> </div> <HTML xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:msxsl="urn:schemas-microsoft-com:xslt" xmlns:nll="uuid:{D3B28627-934D-41bc-8B7A-0549A8802FE4}"> <HEAD> <META http-equiv="Content-Type" content="text/html; charset=UTF-16"> </HEAD> <div id="infobar"><a href="javascript:;" accesskey="r" Name="Route" title="Route" class="quickkey"><em class="mnemonic">R</em>oute </a>:<div class="searchtips" style="float:right;margin-right:10px;color: rgb(47, 79, 79);"> <a style="text-decoration:none;color: rgb(47, 79, 79);" title="search tips" name="searchtip" href="../help.aspx#searching" target="_blank"><em class="mnemonic">S</em>earch tips</a></div><ul class="breadcrumb"> <li><a href="/GAC" name="GAC" title="GAC">GA R&amp;R</a></li> <li>&raquo; <a href="/GAC/480" title="480">Department 480</a></li> <li>&raquo; Chapter 480-34</li> </ul> </div> </div><div id="doc" class="container"> <div id="doc-content" class="content"> <h1><nllchapter>Chapter 480-34 CONTROLLED SUBSTANCES</nllchapter></h1> <h2><a href="/GAC/480-34-.01" name="480-34-.01" title="480-34-.01">Rule 480-34-.01 Carisoprodol</a></h2> <P>This rule was adopted to protect the health, safety, and welfare of the public. This rule places Carisoprodol (known as Soma) under Schedule IV, of the Georgia Controlled Substances Act, Code Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-28&amp;title=16#16-13-28(a)" target="_newtab">16-13-28(a)</a>(2-25). The Board finds that:</P> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Carisoprodol has a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It appears to have an addictive effect on the human body;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is regarded as a threat to public health and safety by other states, as well as the U.S. Drug Enforcement Administration;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has a history of increasing abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> The abuse and need to obtain the drug results in multiple uses and combinations, and multiple violations of the law;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has the same risk the public health of the citizens of the state of Georgia as any substance already contained in the Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(g)">(g)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has shown great potential for physiological dependence;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(h)">(h)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is not a precursor of a substance already scheduled in Georgia;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.01(i)">(i)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is about to be placed under Schedule IV of the federal Controlled Substances Act.</td> </tr> </table> <h2><a href="/GAC/480-34-.02" name="480-34-.02" title="480-34-.02">Rule 480-34-.02 Ketamine</a></h2> <P>This rule was adopted to protect the health, safety, and welfare of the public. This rule places Ketamine under Schedule III of the Georgia Controlled Substances Act, Code Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-27&amp;title=16#16-13-27(8)" target="_newtab">16-13-27(8)</a>. The Board finds:</P> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Ketamine has an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of Ketamine demonstrate that the public would be at risk if it is not regulated as a controlled substance;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of Ketamine and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of Ketamine;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Ketamine has the same risk to the public health of citizens of the State of Georgia as any substance already contained in the Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Ketamine has no known precursor already scheduled under the Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.02(g)">(g)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the DEA has filed the intent to add Ketamine to the Federal Controlled Substances Act under Schedule III.</td> </tr> </table> <h2><a href="/GAC/480-34-.03" name="480-34-.03" title="480-34-.03">Rule 480-34-.03 Sodium Oxybate</a></h2> <P>This Chapter was adopted to protect the health, safety, and welfare of the public. This Chapter places Sodium Oxybate (known as Xyrem) that is contained in a drug product for which an application has been approved under Section 505 of the Federal Food, Drug and Cosmetic Act under Schedule III, of the Georgia Controlled Substances Act, Code Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-28&amp;title=16#16-13-28(a)" target="_newtab">16-13-28(a)</a>(2-25). The Board finds that:</P> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Sodium Oxybate has a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It appears to have an addictive effect on the human body;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is regarded as a threat to public health and safety by other states, as well as the U.S. Drug Enforcement Administration;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has a history of increasing abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> The abuse and need to obtain the drug results in multiple uses and combinations, and multiple violations of the law;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has the same risk to the public health of the citizens of the state of Georgia as any substance already contained in the Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(g)">(g)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It has shown great potential for physiological dependence;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(h)">(h)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is not a precursor of a substance already scheduled in Georgia;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.03(i)">(i)</a></td> <td valign="top" style="text-align:left" class="leftalign"> It is about to be placed under Schedule III of the federal Controlled Substances Act.</td> </tr> </table> <h2><a href="/GAC/480-34-.04" name="480-34-.04" title="480-34-.04">Rule 480-34-.04 Synthetic Cannabinoids</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places newly identified compounds, including any material, compound, mixture, or preparation which contains these substances or their derivatives, salts, isomers, or salts of isomers, halogen analogues, and/or homologues, collectively known as Synthetic Cannabinoids, under Schedule I, of the Georgia Controlled Substances Act, Code Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-25&amp;title=16#16-13-25(12)" target="_newtab">16-13-25(12)</a>as follows: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(M)">(M)</a></td> <td valign="top" style="text-align:left" class="leftalign"> (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (UR-144) </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(N)">(N)</a></td> <td valign="top" style="text-align:left" class="leftalign"> [1-(5-fluoropentyl)indole-3yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR11)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(O)">(O)</a></td> <td valign="top" style="text-align:left" class="leftalign"> [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester (URB602)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(P)">(P)</a></td> <td valign="top" style="text-align:left" class="leftalign"> [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (A-796,260)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(Q)">(Q)</a></td> <td valign="top" style="text-align:left" class="leftalign"> [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597).</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(R)">(R)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one (URB754)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(S)">(S)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide (AKB48)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(T)">(T)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-pentyl-3-(1-adamantylamido)indole (2NE1)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(U)">(U)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-(5-fluoropentyl)-N-tricyclo[3.31.13,7]dec-1-yl-1H-indole-3-carboxamide (STS-135)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(V)">(V)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone (CB-13)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(W)">(W)</a></td> <td valign="top" style="text-align:left" class="leftalign"> (1-(5-chloropentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Chloro-UR-144)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(X)">(X)</a></td> <td valign="top" style="text-align:left" class="leftalign"> (1-(5-bromopentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Bromo-UR- 144) </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(Y)">(Y)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(Z)">(Z)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-Fluoro-ADBICA) </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(aa)">(aa)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5fluoro-ABICA)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(bb)">(bb)</a></td> <td valign="top" style="text-align:left" class="leftalign"> (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(cc)">(cc)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(dd)">(dd)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone (THJ 018);</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(ee)">(ee)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (BB-22);</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(1)(ff)">(ff)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201). </td> </tr> </table> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Synthetic Cannabinoids have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have no known precursor already scheduled under the Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.04(2)(g)">(g)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.05" name="480-34-.05" title="480-34-.05">Rule 480-34-.05 Synthetic Cathinones</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places an additional newly identified compound, including any material, compound, mixture, or preparation which contains these substances or their derivatives, salts, isomers, or salts of isomers, halogen analogues, or homologues, collectively known as a Synthetic Cathinone, under Schedule I, of the Georgia Controlled Substances Act, Code Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-25&amp;title=16#16-13-25(12)" target="_newtab">16-13-25(12)</a>as follows: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(1)(aa)">(aa)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N-acetyl-3,4-methylenedioxymethcathinone</td> </tr> </table> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Synthetic Cathinones have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have no known precursor already scheduled under the Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.05(2)(g)">(g)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.06" name="480-34-.06" title="480-34-.06">Rule 480-34-.06 Hydrocodone Combination Products</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Effective October 6, 2014, Official Code of Georgia Annotated (O.C.G.A.) §§ <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-27&amp;title=16#16-13-27(4)(C)" target="_newtab">16-13-27(4)(C)</a>, <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-27&amp;title=16&amp;getbrowsepage=yes#16-13-27(4)(D)" target="_newtab">16-13-27(4)(D)</a> are hereby removed from Schedule III of the Georgia Controlled Substances Act, O.C.G.A. 16-13-25, et. seq. The following language shall be deleted from O.C.G.A. §§ <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-27&amp;title=16#16-13-27(4)" target="_newtab">16-13-27(4)</a>: "(C) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (D) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts."</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Effective October 6, 2014, all Hydrocodone Combination Products (HCPs) in the State of Georgia are Schedule II controlled substances. <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Each registrant possessing HCPs must make an actual count inventory of all HCPs as of October 6, 2014 and maintain it with the registrant's biennial DEA inventory.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> All HCPs products must be treated as any other Schedule II controlled substance. There can be no oral prescriptions except in the case of an emergency, and all hard-copy HCP prescriptions must be issued on security paper.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> For any HCP prescription written and filled before October 6, 2014 with authorized refills, the prescription can be refilled only for the authorized number of refills prior to April 8, 2015.</td> </tr> </table> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)">(3)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that as Schedule III controlled substances, HCPs have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of HCPs demonstrate that the public is at extreme risk if HCPs are not regulated as Schedule II controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the history and pattern of abuse of HCPs as a Schedule III controlled substance and the scope and significance of that abuse support stricter regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that as a Schedule III controlled substance, there exists an imminent peril to the public health and welfare with regard to the abuse of HCPs;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that HCPs have the same risk to the public health of citizens of the State of Georgia as other Schedule II controlled substances already contained in the Georgia Controlled Substances Act;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.06(3)(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that as of October 6, 2014, the U.S. Drug Enforcement Administration has removed all reference to HCPs from Schedule III of <a href="https://links.casemakerlegal.com/states/us/books/Code_of_Federal_Regulations/browse?ci=25&amp;id=gasos&amp;codesec=1308.13&amp;title=21#" target="_newtab">21 CFR 1308.13</a>, which places all HCPs under Schedule II of <a href="https://links.casemakerlegal.com/states/us/books/Code_of_Federal_Regulations/browse?ci=25&amp;id=gasos&amp;codesec=1308.12&amp;title=21#" target="_newtab">21 CFR 1308.12</a>.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.07" name="480-34-.07" title="480-34-.07">Rule 480-34-.07 Hallucinogens</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, including any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers (whether optical, position, or geometrics), and salts of isomers under Schedule I of the Georgia Controlled Substances Act, Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-25&amp;title=16#16-13-25(3)" target="_newtab">16-13-25(3)</a>as follows: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)(BBBB)">(BBBB)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Methoxyphencyclidine (MeO-PCP)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)(CCCC)">(CCCC)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 4-hydroxy-N-methyl-N-isopropyltryptamine (4-OH-MiPT)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)(DDDD)">(DDDD)</a></td> <td valign="top" style="text-align:left" class="leftalign"> N,[ALPHA]-dimethyl-5-benzofuranethanamine (5-MAPB)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)(EEEE)">(EEEE)</a></td> <td valign="top" style="text-align:left" class="leftalign"> 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (SDB-006)</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(1)(FFFF)">(FFFF)</a></td> <td valign="top" style="text-align:left" class="leftalign"> methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA)</td> </tr> </table> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that hallucinogens have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.07(2)(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have no known precursor already scheduled under the Act.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.08" name="480-34-.08" title="480-34-.08">Rule 480-34-.08 Lidocaine</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.08(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. Lidocaine topical, 40 mg/gm. or less (4.0%) is deleted from Official Code of Georgia Annotated (O.C.G.A.) § <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-71&amp;title=16#16-13-71(b)(520)" target="_newtab">16-13-71(b)(520)</a>.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.08(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.08(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that lidocaine topical, 40 mg/gm. or less (4.0%) does not have a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.08(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Board has considered the scientific evidence of its pharmacological effects, the state of current scientific knowledge regarding the drug, the history and current pattern of abuse, the scope, duration, and significance of abuse, the potential of the drug to produce psychic or physiological dependence liability; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.08(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the drug is no longer included as a prescription drug under the Federal Food, Drug, and Cosmetic Act, <a href="https://links.casemakerlegal.com/states/us/books/United_States_Code/browse?ci=25&amp;id=gasos&amp;codesec=301&amp;title=21&amp;getbrowsepage=yes#" target="_newtab">21 U.S.C. Section 301</a>, et. seq., as amended.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.09" name="480-34-.09" title="480-34-.09">Rule 480-34-.09 Additional Compounds under Schedule IV</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places additional newly identified compounds, including any material, compound, mixture, or preparation which contains any quantity of the following substances, their salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specified chemical designation, including as having a stimulant or depressant effect on the central nervous system or a hallucinogenic effect, under Schedule IV of the Georgia Controlled Substances Act, Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-28&amp;title=16#" target="_newtab">16-13-28</a> as follows: <P>(14.3) Flubromazepam</P> <P>(30.07) Pyrazolam</P> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that benzodiazepines have a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(d)">(d)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(e)">(e)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule IV under the Controlled Substances Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.09(2)(f)">(f)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have no known precursor already scheduled under the Act.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.10" name="480-34-.10" title="480-34-.10">Rule 480-34-.10 Synthetic Opiates</a></h2> <P>This rule was adopted to protect the health, safety, and welfare of the public. This rule places newly identified compounds, including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, or salts is possible within the specific chemical designation under Schedule I of the Georgia Controlled Substances Act, Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-25&amp;title=16#16-13-25(1)" target="_newtab">16-13-25(1)</a>as follows:</P> <P>(RR)<I> trans</I>-3,4-dichloro-<I>N</I>-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700) </P> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that Synthetic Opiates have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(3)">(3)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(4)">(4)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(5)">(5)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.10(b)(6)">(6)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that these compounds have no known precursor already scheduled under the Act.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.11" name="480-34-.11" title="480-34-.11">Rule 480-34-.11 Levocetirizine Dihydrochloride</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.11(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. Levocetirizine dihydrochloride in 5 mg tablets or an oral solution of 2.5 mg per 5 mL (.05 mg per mL), as identified in Official Code of Georgia Annotated (O.C.G.A.) § <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-71&amp;title=16#16-13-71(b)" target="_newtab">16-13-71(b)</a>(516.75), is hereby removed from the list of dangerous drugs of the Georgia Dangerous Drugs Act.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.11(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.11(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that levocetirizine dihydrochloride does not have a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.11(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Board has considered the scientific evidence of its pharmacological effects; the state of current scientific knowledge regarding the drug; the history and current pattern of abuse; the scope, duration, and significance of abuse; the potential of the drug to produce psychic or physiological dependence liability; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.11(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the drug, when in 5 mg tablets or an oral solution of 2.5 mg per 5 mL (.05 mg per mL), has been approved for non-prescription status by the Federal Food and Drug Administration.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.12" name="480-34-.12" title="480-34-.12">Rule 480-34-.12 Synthetic Fentanyl</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places newly identified compounds, including any derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from fentanyl, and whether or not further modified in any of the following ways under Schedule I of the Georgia Controlled Substances Act, Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-25&amp;title=16#16-13-25(13)" target="_newtab">16-13-25(13)</a>as follows: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(a)(H)">(H)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Tetrahydrofuran fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide)</td> </tr> </table> </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That synthetic fentanyls have an extremely high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(3)">(3)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(4)">(4)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(5)">(5)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.12(b)(6)">(6)</a></td> <td valign="top" style="text-align:left" class="leftalign"> That these compounds have no known precursor already scheduled under the Act.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.13" name="480-34-.13" title="480-34-.13">Rule 480-34-.13 Triamcinolone Acetonide Nasal Spray</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.13(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. Triamcinolone acetonide nasal spray 55mcg per spray or less, is hereby deleted from the dangerous drug list as referenced in the Official Code of Georgia Annotated (O.C.G.A.) § <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-71&amp;title=16#16-13-71(b)(976)" target="_newtab">16-13-71(b)(976)</a>.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.13(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.13(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that triamcinolone acetonide nasal spray 55mcg per spray or less does not have a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.13(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Board has considered the scientific evidence of its pharmacological effects; the state of current scientific knowledge regarding the drug; the history and current pattern of abuse; the scope, duration, and significance of abuse; the potential of the drug to produce psychic or physiological dependence liability; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.13(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the drug, when in nasal spray form of 55mcg per spray or less has been approved for non-prescription status by the Federal Food and Drug Administration.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.14" name="480-34-.14" title="480-34-.14">Rule 480-34-.14 Sodium Chloride Injection for Catheter Flush</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.14(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. Sodium chloride injection in quantities of 10cc or less, when used as a catheter flush solution to act by physically occupying space within a catheter and exerting pressure on the patient's circulating blood, is hereby deleted from the dangerous drug list as referenced in Official Code of Georgia Annotated (O.C.G.A.) § <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-71&amp;title=16#16-13-71(b)(867)" target="_newtab">16-13-71(b)(867)</a>.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.14(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.14(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that sodium chloride injection in quantities of 10cc or less does not have a high potential for abuse;</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.14(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Board has considered the scientific evidence of its pharmacological effects, the state of current scientific knowledge regarding the drug, the history and current pattern of abuse, the scope, duration, and significance of abuse, the potential of the drug to produce psychic or physiological dependence liability; and</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.14(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Federal Food and Drug Administration concluded that sodium chloride injection (saline injection or flush), when used as a catheter flush solution and acting in this manner, this solution meets the definition of a device in that it affects the structure or function of the body, and does not achieve its primary intended purposes through chemical or metabolic action.</td> </tr> </table> </td> </tr> </table> <h2><a href="/GAC/480-34-.15" name="480-34-.15" title="480-34-.15">Rule 480-34-.15 Additional Compounds under Schedule V</a></h2> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(1)">(1)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule was adopted to protect the health, safety, and welfare of the public. This rule places an additional compound as specifically identified here under Schedule V of the Georgia Controlled Substances Act, Section <a href="https://links.casemakerlegal.com/states/ga/books/Code_of_Georgia/browse?ci=25&amp;id=gasos&amp;codesec=16-13-29&amp;title=16#" target="_newtab">16-13-29</a> as follows: </td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(1.5)">(1.5)</a></td> <td valign="top" style="text-align:left" class="leftalign"> Epidiolex: A drug product in finished dosage formulation in its original container that has been approved by and labelled in compliance with the U.S. Food and Drug Administration (FDA) that contains cannabidiol (CBD) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(2)">(2)</a></td> <td valign="top" style="text-align:left" class="leftalign"> This rule is based on the following findings of the Board: <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(2)(a)">(a)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the FDA approved the drug Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. Epidiolex is an oral solution that contains CBD extracted from the cannabis plant.</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(2)(b)">(b)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the U.S. Drug Enforcement Administration (DEA) did seek a medical and scientific evaluation or scheduling recommendation from the U.S. Department of Health and Human Services (HHS) with respect to the Epidiolex formulation. In responding to that request, HHS advised DEA that it found the Epidiolex formulation to have a very low potential for abuse and therefore, recommended that if DEA concluded that control of the drug was required under the Single Convention, Epidiolex should be placed in Schedule V of the Federal Controlled Substance Act (CSA).</td> </tr> </table> <table border="0" width="100%" cellspacing="4" cellpadding="4"> <tr> <td valign="top" width="1%" style="white-space:nowrap;text-align:left;width:18px;"><a style="white-space:nowrap;" name="480-34-.15(2)(c)">(c)</a></td> <td valign="top" style="text-align:left" class="leftalign"> that the Board has considered, based on available information, the potential for abuse; scientific evidence of its pharmacological effects; the state of current scientific knowledge regarding the drug; the history and current pattern of abuse; the scope, duration, and significance of abuse; and the potential of the drug to produce psychic or physiological dependence liability.</td> </tr> </table> </td> </tr> </table> </div> </div> </HTML> </div> <div id="toc" class="sidebar noprint"> <ul id="toc-children" class="children"><li><a href="/GAC/480-34-.01" name="480-34-.01" title="480-34-.01">Rule 480-34-.01 Carisoprodol</a></li><li><a href="/GAC/480-34-.02" name="480-34-.02" title="480-34-.02">Rule 480-34-.02 Ketamine</a></li><li><a href="/GAC/480-34-.03" name="480-34-.03" title="480-34-.03">Rule 480-34-.03 Sodium Oxybate</a></li><li><a href="/GAC/480-34-.04" name="480-34-.04" title="480-34-.04">Rule 480-34-.04 Synthetic Cannabinoids</a></li><li><a href="/GAC/480-34-.05" name="480-34-.05" title="480-34-.05">Rule 480-34-.05 Synthetic Cathinones</a></li><li><a href="/GAC/480-34-.06" name="480-34-.06" title="480-34-.06">Rule 480-34-.06 Hydrocodone Combination Products</a></li><li><a href="/GAC/480-34-.07" name="480-34-.07" title="480-34-.07">Rule 480-34-.07 Hallucinogens</a></li><li><a href="/GAC/480-34-.08" name="480-34-.08" title="480-34-.08">Rule 480-34-.08 Lidocaine</a></li><li><a href="/GAC/480-34-.09" name="480-34-.09" title="480-34-.09">Rule 480-34-.09 Additional Compounds under Schedule IV</a></li><li><a href="/GAC/480-34-.10" name="480-34-.10" title="480-34-.10">Rule 480-34-.10 Synthetic Opiates</a></li><li><a href="/GAC/480-34-.11" name="480-34-.11" title="480-34-.11">Rule 480-34-.11 Levocetirizine Dihydrochloride</a></li><li><a href="/GAC/480-34-.12" name="480-34-.12" title="480-34-.12">Rule 480-34-.12 Synthetic Fentanyl</a></li><li><a href="/GAC/480-34-.13" name="480-34-.13" title="480-34-.13">Rule 480-34-.13 Triamcinolone Acetonide Nasal Spray</a></li><li><a href="/GAC/480-34-.14" name="480-34-.14" title="480-34-.14">Rule 480-34-.14 Sodium Chloride Injection for Catheter Flush</a></li><li><a href="/GAC/480-34-.15" name="480-34-.15" title="480-34-.15">Rule 480-34-.15 Additional Compounds under Schedule V</a></li></ul> </div> </div> <!--content ends here--> <div id="footer" class="noprint"><span class="footer">Copyright &copy; 2019 Lawriter LLC - All rights reserved.</span>| <a href="mailto:support@casemakerlegal.com?subject=Rules and Regulations of the State of Georgia">Email Us</a> | 844-838-0769 | <a href="http://livechat.casemakerlegal.com/client.php?locale=en" target="_blank" onclick="if(navigator.userAgent.toLowerCase().indexOf('opera') != -1 && window.event.preventDefault)window.event.preventDefault();this.newWindow = window.open('http://livechat.casemakerlegal.com/client.php?locale=en&url='+escape(document.location.href)+'&referrer='+escape(document.referrer), 'webim','toolbar=0,scrollbars=0,location=0,status=1,menubar=0,width=640,height=480,resizable=1');this.newWindow.focus();this.newWindow.opener=window;return false;">Live Chat</a> </div> </div> </body> </html>